Clinical Trial Update: A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update for AP301, an iron-based phosphate binder, evaluating its use for hyperphosphatemia in patients with chronic kidney disease on d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease
• Hyperphosphatemia

Drugs mentioned

• AP301

Snippet

Sponsor: Alebund Pharmaceuticals | Conditions: Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis | Phase 3 | Status: RECRUITING